Burning feet, numbness, tingling and sleep loss are early warning signs of nerve damage. We detect it early — before it becomes irreversible — using FDA-cleared point-of-care nerve conduction testing.
Diabetic peripheral neuropathy (DPN) develops silently. Up to 50% of patients remain asymptomatic until the condition reaches advanced stages — by which point damage is often permanent. Traditional monofilament testing catches only the most obvious cases.
Nerve conduction studies can detect up to 3× more asymptomatic neuropathy than monofilament testing. That's why every neuropathy assessment at Boston Diabetes begins with objective measurement, not guesswork.
An FDA-cleared, non-invasive test with ~90% sensitivity vs EMG, delivering objective results in 10–15 seconds — trusted in over 2 million assessments worldwide.
Every program follows the same three-stage pathway — comprehensive assessment, personalized intervention, and continuous outcome measurement.
DPN Check® nerve conduction test, foot examination, risk stratification and review of your history and glucose control.
A tailored plan combining glycaemic optimisation, nerve-protective therapy, pain management and lifestyle support.
Repeat testing tracks whether nerve function stabilises or improves — so care is guided by results, not assumptions.